What do human pregnancy data show about zidovudine and the risk of birth defects?

Human pregnancy data for zidovudine (Retrovir), including more than 3,000 first-trimester and more than 3,000 second- and third-trimester exposure outcomes, indicate no malformative toxicity, making birth defects unlikely; Retrovir can be used during pregnancy if clinically needed.